# Ixazomib for Desensitization

> **NCT03213158** · PHASE2 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 10 (actual)

## Conditions studied

- Kidney Diseases
- End Stage Renal Disease

## Interventions

- **DRUG:** Ixazomib Oral Capsule

## Key facts

- **NCT ID:** NCT03213158
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-15
- **Primary completion:** 2021-04-16
- **Final completion:** 2021-04-16
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03213158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03213158, "Ixazomib for Desensitization". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03213158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*